Targeted drug delivery would be performed by creating 3 antibody binding domains for antigens CA125, KASH5, and HSF1 on a liposome. To test for the presence of these antigens in the HGSOC, we would perform an enzyme linked immunosorbent assay (ELISA) for autoantibody (AAb) reactivity. Autoantibodies for these three antigens will be present in the blood, so ELISA will would tell us if the antibodies for these particular antigens were present. To test for treatment progression, periodic ELISA assays will be performed. If the autoantibody levels in the blood remain high, more treatment is needed. A possible indication of cancer evolution and/or metastasis is if less than three autoantibodies remain high. In this event, a new liposome with only the respective two monoclonal antibodies will need to be engineered.
Recent comments